Merck (MRK) Dividend Coverage Ratio Growth (1y) (2010 - 2026)
Powered by 
Analysis
Merck (MRK) Dividend Coverage Ratio Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Div. Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.24 Bn | 625.48 Bn | 17.26 Bn | -3.09% |
| 2 | AbbVie | 441.52 Bn | 434.96 Bn | 12.70 Bn | 264.24% |
| 3 | Merck | 365.75 Bn | 358.60 Bn | 12.21 Bn | -129.25% |
| 4 | Novartis Ag | 266.61 Bn | 258.92 Bn | 11.24 Bn | -30.09% |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn | -108.11% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -92.21% |
| 7 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.43 Bn | 18.77 Bn | 683.80 Mn | - |
| 10 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -129.25% |
| Mar 31, 2026 | -181.26% |
| Dec 31, 2025 | -23.51% |
| Sep 30, 2025 | 76.04% |
| Jun 30, 2025 | -22.47% |
| Mar 31, 2025 | 1.47% |
| Dec 31, 2024 | 389.89% |
| Sep 30, 2024 | -36.79% |
| Jun 30, 2024 | 186.79% |
| Mar 31, 2024 | 60.35% |
| Dec 31, 2023 | -138.39% |
| Sep 30, 2023 | 37.52% |
| Jun 30, 2023 | -242.00% |
| Mar 31, 2023 | -38.23% |
| Dec 31, 2022 | -24.68% |
| Sep 30, 2022 | -32.83% |
| Jun 30, 2022 | 141.44% |
| Mar 31, 2022 | 27.44% |
| Dec 31, 2021 | 268.85% |
| Sep 30, 2021 | 45.42% |